First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial - Lee, SM; Khan, I; Upadhyay, S (The Lancet Oncology, 2012)
et al.